eli lilly tirzepatide fda approval OKs Zepbound for weight-loss Compounders protest as FDA removes

Dasatinib+Quercetin (D+Q) inhibit multiple BCL-2 family pro-survival proteins and tyrosine kinasesbroad-mechanism senolytics with human clinical trial data (Mayo Clinic studies)

In addition, a single injection of the antibody decreased fasting blood glucose levels in a dose-dependent manner in normal C57BL/6 mice without inducing hypoglycemia, and improved glucose tolerance

Science Advances

A 2025 survey by the health-policy research firm KFF found that amont companies that offer health benefits and have 5,000 or more workers, the number covering GLP-1s for weight loss increased significantly from 2024, rising from 28% to 43%, though the majority of employer-based health insurances don't cover GLP-1s for weight loss